The Technical Analyst
DermTech Inc [DMTK]
Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
DermTech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.66% $0.585
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.27 mill |
| EPS: | -3.09 |
| P/E: | -0.190 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 34.62 mill |
| Avg Daily Volume: | 0.297 mill |
| RATING 2024-04-25 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.190 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.190 | industry: PE 18.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.519 - 0.649 ( +/- 11.13%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-10 | Sun Kevin M | Sell | 445 | Common Stock |
| 2024-03-05 | Sun Kevin M | Buy | 0 | |
| 2024-03-05 | Akhavan Ramin | Sell | 1 758 | Common Stock |
| 2024-03-05 | Akhavan Ramin | Sell | 1 989 | Common Stock |
| 2024-03-05 | Sun Kevin M | Sell | 180 | Common Stock |
| INSIDER POWER |
|---|
| 72.33 |
| Last 97 transactions |
| Buy: 1 415 350 | Sell: 282 150 |
Forecast:
16:00 - $0.583
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.583
Forecast 2: 16:00 - $0.583
Forecast 3: 16:00 - $0.583
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.585 (-4.66% ) |
| Volume | 0.179 mill |
| Avg. Vol. | 0.297 mill |
| % of Avg. Vol | 60.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DMTK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DMTK
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Latest Press Releases
2024-04-18 16:15:00 - Press Release
Dermtech To Explore Strategic Alternatives And Implement Restructuring Plan
San diego--(business wire)--dermtech, inc. (nasdaq: dmtk) (dermtech or the company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that the special committee of its board of directors engaged td cowen to conduct a process exploring strategic alternatives to maximize stockholder value. potential strategic alternatives that may be explored or evaluated include an acquisition, merger, reverse merger, business combination, sale of assets, lice.
2024-03-08 08:05:00 - Press Release
Dermtech Presents Research Abstracts At The 2024 American Academy Of Dermatology (aad) Annual Meeting And New Research Published In The Journal Of Investigative Dermatology
San diego--(business wire)--dermtech, inc. (nasdaq: dmtk) (dermtech or the company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 american academy of dermatology (aad) annual meeting, taking place march 8th-12th in san diego, california. the first research abstract, “non-invasive gene expression analyses to rule out melanoma in patients with fitzpatrick skin types iv-vi” will be prese.
2024-02-29 16:01:00 - Press Release
Dermtech Reports Fourth-quarter 2023 Financial Results
San diego--(business wire)--dermtech, inc. (nasdaq: dmtk) (dermtech or the company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its fourth-quarter 2023 financial results. “we reported sustained improvement in many of our key performance indicators during the second half of last year and will continue emphasizing average selling price (asp) and revenue growth in 2024,” said bret christensen, ceo, dermtech. “we've aligned our commercial ef.
2024-02-13 08:05:00 - Press Release
Dermtech Announces Release Date For Fourth-quarter 2023 Financial Results
San diego--(business wire)--dermtech, inc. (nasdaq: dmtk) (dermtech or the company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, will host a conference call and webcast on thursday, february 29, 2024 at 5:00 p.m. eastern time (et) to discuss the company's fourth-quarter 2023 operating and financial results. in advance of the call on february 29, 2024, dermtech will issue its fourth-quarter 2023 earnings press release. for participants interested in aski.
2024-01-31 16:30:00 - Press Release
Dermtech Announces Additional Restructuring Actions To Focus On Revenue Growth And Streamline Operations
San diego--(business wire)--dermtech, inc. (nasdaq: dmtk) (dermtech or the company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses. the company has continued to rigorously evaluate its growth opportunities and operations, while dedicating substantially all of its resources to growing reimbursed dermtech melanom.
Latest News
2024-02-29 18:26:04 - Zacks Investment Research
DermTech, Inc. (DMTK) Reports Q4 Loss, Misses Revenue Estimates
DermTech, Inc. (DMTK) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.93 per share a year ago.
2023-08-03 22:58:03 - Seeking Alpha
DermTech, Inc. (DMTK) Q2 2023 Earnings Call Transcript
DermTech, Inc. (NASDAQ:DMTK ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head, Investor Relations Bret Christensen - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Operator Good day, and thank you for standing by. Welcome to DermTech's Second Quarter 2023 Financial Results Call.
2023-06-20 05:25:00 - The Motley Fool
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
Nano-X is marketing a different type of X-ray system. DermTech's Smart Sticker system could change dermatology.
2023-05-04 19:01:33 - Zacks Investment Research
DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates
DermTech, Inc. (DMTK) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.01 per share a year ago.
2023-03-03 08:05:00 - Business Wire
DermTech to Present at March Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that management is scheduled to present at the following investor conferences during March 2023. TD Cowen 43rd Annual Health Care Conference, Boston – fireside chat on March 8, 2023 at 1:30 p.m. ET. Oppenheimer 33rd Annual Healthcare Conference, Virtual – presentation on March 14, 2023 at 10:00 a.m.
2023-03-02 20:51:03 - Seeking Alpha
DermTech, Inc. (DMTK) Q4 2022 Earnings Call Transcript
DermTech, Inc. (NASDAQ:DMTK ) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Stephanie Yan - Cowen Mark Massaro - BTIG Francois Brisebois - Oppenheimer Andrew Brackmann - William Blair Jacob Johnson - Stephens Operator Good day and thank you for standing by. Welcome to DermTech's Fourth Quarter 2022 Financial Results Conference Call.
2023-03-02 18:49:33 - Zacks Investment Research
DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.12% and 19.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-02-10 08:30:00 - Business Wire
DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, March 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2022 operating and financial results. In advance of the call on March 2, 2023, DermTech will issue its fourth-quarter 2022 earnings press release.
2023-01-22 05:59:20 - Seeking Alpha
DermTech: Momentum Rising With TRICARE
The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has been modest due to various launch barriers. Nevertheless, the company is exerting strong efforts to improve success.
2023-01-18 05:55:00 - The Motley Fool
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run
